Loading
Co-discovered EGFR mutations in lung cancer and linked Fusobacterium to colorectal cancer.
Matthew Meyerson is Director of the Center for Cancer Genomics at Dana-Farber and an Institute Member of the Broad Institute of MIT and Harvard. He is a genomicist known for co-discovering EGFR mutations in lung cancer in 2004, mapping lung adenocarcinoma genomes for The Cancer Genome Atlas, and identifying enrichment of Fusobacterium nucleatum in colorectal tumours. His selected papers report EGFR mutations in lung cancer correlating with response to gefitinib, and the genomic analysis associating Fusobacterium with colorectal carcinoma. He continues to work on lung cancer genomics and the microbiome in cancer.
| Title | Journal | Year |
|---|---|---|
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Science | 2004 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma | Genome Research | 2012 |
It is the empirical basis for treating the two histologies as separate diseases for targeted therapy and as one disease for immunotherapy, which is exactly how they are treated.
It is the reference table the field still argues against, and it made two practical points that outlived it: a tumour with no driver on a standard panel usually has one that the panel did not look for, and pathway activity measured on protein does not follow from the mutation list.
Resistance to a targeted drug usually has a cause you can read off a sequence, which means it can be targeted in turn. Osimertinib exists because of this paper.
Why a drug can look useless in one trial and transformative in another: the trials had different proportions of the patients the drug was for. It is the argument for genotyping before drawing conclusions from a response rate.
Shares Comprehensive molecular profiling of lung adenocarcinoma, Non-small-cell lung cancer.
Shares Comprehensive molecular profiling of lung adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer.
Shares EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, EGFR, Non-small-cell lung cancer.
Shares EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, EGFR, Non-small-cell lung cancer.
Shares Comprehensive molecular profiling of lung adenocarcinoma, Non-small-cell lung cancer.
Shares Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas, Comprehensive molecular profiling of lung adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer.
Shares Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas, Comprehensive molecular profiling of lung adenocarcinoma, Non-small-cell lung cancer.
Shares Comprehensive molecular profiling of lung adenocarcinoma, Non-small-cell lung cancer.